Asset
VILOBELIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01319903 | phase1 | completed | 2011-03-01 | 2011-10-01 | InflaRx GmbH | Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 |
| NCT03487276 | phase2 | completed | 2018-02-26 | 2019-05-27 | InflaRx GmbH | Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) |
| NCT03971643 | phase2 | completed | 2019-05-16 | 2022-01-03 | InflaRx GmbH | Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum |
| NCT04812535 | phase2 | terminated | 2021-03-31 | 2024-06-04 | InflaRx GmbH | Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC. |
| NCT05964413 | phase3 | terminated | 2023-11-01 | 2025-07-11 | InflaRx GmbH | Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum |
FDA applications (0)
This company has no applications containing this asset.